贵州百灵（002424）收到千万罚单，连续四年财务造假，两类投资者可追损

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, following the issuance of a notice of investigation [1][5] Summary by Sections Investigation Details - The company has received a notice of investigation from the CSRC and is currently being investigated for potential violations of information disclosure regulations [1][5] - A lawyer from Shanghai Baiyue Law Firm indicated that affected investors may have the right to file lawsuits for compensation once the CSRC's investigation concludes [1][5] Compensation Conditions - Investors who traded Guizhou BaiLing stock (002424) during specific periods and incurred losses may qualify for preliminary compensation registration: - Those who bought shares between April 30, 2020, and April 30, 2024, and held or sold at a loss after April 30, 2024 [2][6] - Those who bought shares between April 23, 2022, and April 30, 2024, and held or sold at a loss after April 30, 2024 [2][6] - The final compensation conditions will be determined by the formal administrative penalty decision from the CSRC and the effective ruling from the people's court [2][6] Required Documentation for Compensation - To initiate the compensation process, investors typically need to prepare the following documents: - Original transaction statements for Guizhou BaiLing stock, stamped by the brokerage firm [3][6] - A copy of the investor's ID (or business license for institutional investors) [4][7] - A confirmation of the securities account information from the brokerage [4][7]